QUINTILES ACQUIRES CENTRAL AMERICAN RESEARCH ORGANIZATION
Bio-Trials to Complement Existing Quintiles Latin American Organization
RESEARCH TRIANGLE PARK, N.C. – October 30, 2007 – Quintiles Transnational Corp. today announced that its Latin American subsidiary has purchased Bio-Trials, a leading Central American Clinical Research Organization (CRO) with headquarters in Panama and offices in Costa Rica, Guatemala, Ecuador and Peru.
Bio-Trials provides clinical monitoring, clinical site coordination, regulatory support, study management and supply distribution services. It has conducted about 30 clinical trials in 10 Central and South American countries, and its customers have included a number of major pharmaceutical companies and global CROs.
“The acquisition of Bio-Trials gives Quintiles an experienced, well-established team as well as access to an experienced network of independent investigators in the increasingly important Central American region,” said Jeff Thomis, President of Global Clinical Development Services for Quintiles. “Our customers are increasingly including Central America as part of their global drug development program. The Bio-Trials team will be a welcome addition to our Latin America group.”
In addition to its offices, Bio-Trials has supply distribution points in Panama, Costa Rica, Guatemala and Peru.
ABOUT QUINTILES LATIN AMERICA
Quintiles Latin America was founded in 1995 and now has nearly 600 employees in six countries, with headquarters in Argentina, providing project management, clinical trial monitoring, regulatory, drug safety, site management, quality assurance, central laboratory and clinical trial supplies services. Quintiles Latin America has conducted more than 300 studies involving more than 30,000 patients.
ABOUT QUINTILES INTERNATIONAL
Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the pharmaceutical, biotechnology and healthcare industries. With more than 19,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company’s Web site at www.qtrn.com.
Fairmount Partners is a registered Broker Dealer, member FINRA (www.finra.org) and SIPC (www.sipc.org).
Principals of Fairmount Partners acted as advisors to Bio-Trials in this transaction.
Contact: Neal McCarthy